Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response

Inflammopharmacology

Volumn 14, Issue 5-6, 2006, Pages 214-221

  Sikiric, P ^a   Seiwerth, S ^a   Brcic, L ^a   Blagaic, A B ^a   Zoricic, I ^a   Sever, M ^a   Klicek, R ^a   Radic, B ^a   Keller, N ^a   Sipos, K ^a   Jakir, A ^a   Udovicic, M ^a   Tonkic, A ^a   Kokic, N ^a   Turkovic, B ^a   Mise, S ^a   Anic, T ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Cytoprotective agent; Healing; PLD 116; PLD 14736; Stable gastric pentadecapeptide BPC 157 PL 10

Indexed keywords

FAMOTIDINE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYL ALANYLGLYCYLLEUCYLVALINE; GLYCYLGLUTAMYLPROLYLPROLYLPROLYLGLYCYLLYSYLPROLYLALANYLASPARTYLASPARTYLALANYLGLYCYLLEUCYLVALINE; HALOPERIDOL; INDOMETACIN; NITRIC OXIDE; RANITIDINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLOOD VESSEL REACTIVITY; CELL PROTECTION; CLINICAL TRIAL; COLITIS; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; ENDOTHELIUM; ENTERITIS; ESOPHAGITIS; GASTROINTESTINAL DISEASE; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND; SEROTONIN RELEASE; SOMATOSENSORY SYSTEM; STOMACH DISTENSION; STOMACH JUICE; STOMACH MUCOSA; SUBSTANTIA NIGRA; SYSTEMATIC REVIEW; WOUND HEALING;

ANIMALS; ANTI-ULCER AGENTS; CLINICAL TRIALS; CROATIA; DRUG STABILITY; HUMANS; INFLAMMATORY BOWEL DISEASES; LETHAL DOSE 50; PEPTIDE FRAGMENTS; PROTEINS; STOMACH;

EID: 33845912425     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-006-1531-7     Document Type: Conference Paper

References (74)

1. Bedekovic, V., Mise, S., Anic, T. et al. (2003). Different effect of antiulcer agents on rat cysteamine-induced duodenal ulcer after sialoadenectomy, but not gastrectomy. European J. Pharmacol. 477, 73-80.
2. Bilic, I., Zoricic, I., Anic, T. et al. (2001). Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice. Life Sci. 68,1905-1912.
3. Erceg, D., Simicevic, V.N., Kolega, M., Dohoczky, C. (1997). Some aspects of the effects of PL-10.AK-15 on the gastrointestinal tract. J. Physiol. (Paris). 91, 179-181.
4. Holzer, P. (1991). Capsaicin: Cellular targets, mechanisms of action and selectivity for thin sensory neurons. Pharmacol. Rev. 43, 143-201.
5. Jelovac N., Sikiric, P., Rucman, R. et al. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biol. Psychiatry. 43, 511-519.
6. Jelovac N., Sikiric P., Rucman, R. et al. (1999a). Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. European J. Pharmacol. 379, 19-31.
7. Jelovac N., Sikiric P., Rucman, R. et al. (1999b). The effect of a novel pentadecapeptide BPC 157 on development of tolerance and physical dependence following repeated administration of diazepam. Chin. J. Physiol. 42, 171-179.
8. Kalogjera L., Ries M., Baudoin T., Ferencic Z., Trotic R., Pegan B. (1997). Dose-dependent protective effect of BPC 157 on capsaicin-induced rhinitis in rats. Eur. Arch. Otorhinolaryngol. 254, 9-11.
9. Krivic, A., Anic, T., Seiwerth, S., Huljev, D., Sikiric, P. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon to bone healing and opposed corticosteroid aggravation. J. Orthop. Res. 24, 982-989.
10. Krivic, A., Sikiric, P. (2003). Comment on "Use of recombinant human bone morphogenic protein-2 to enhance tendon healing in a bone tunnel". Am. J. Sports Med. 31, 636-637.
11. Lovric-Bencic, M., Sikiric, P., Hanzevacki Separovic, J. et al. (2004). Doxorubicine-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse. J. Pharmacol. Sci. 95, 19-26.
12. Madden, R. J., Ramsburg, H. H., Hundley, J. M. (1951). A critical study of the Shay rat. Gastroenterology 18, 119-127.
13. Menetrey, J., Kasemkijwattana, C., Day, C.S. et al. (2000). Growth factors improve muscle healing in vivo. J. Bone Joint Surg. Br. 82, 131-137.
14. Michell, C. A., McGaechie, J. K., Grounds, M. D. (1996). The exogenous administration of basic growth factor to mice does not enhance the process of regeneration. Growth Factors. 13, 37-55.
15. Mikus, D., Sikiric P., Seiwerth S. et al. (2001). Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice. Burns. 127, 817-827.
16. Mise, S., Tonkic, A., Pesutic, V. et al. (2006). The presentation and organization of adaptive cytoprotection in the rat stomach, duodenum, and colon. Med. Sci. Mon. 12, BR 146-153.
17. Mózsik, G., Sikiric, P., Seiwerth, S. (2005). Pentadecapeptide BPC 157 (PLD116, PL14736, Pliva) influences ATP energy system and antagonizes 0.6 M HCl- and 96% ethanl-gastric lesion in rat. Digestion 73 (Suppl. 2), 41.
18. Pajic, A., Fattorini, I., Gjurasin, M. et al. (2003). Gastric pentadecapeptide BPC 157 (PL-10, PL-116)reduces and reverses peritonitis - intra-abdominal adhesion in normal and sialoadenectomized rat and abolished mortality in corticosteroid-rat. Dig. Dis. Sci. 48, 1894.
19. Pawlik, W. W., Sikiric, P., Brzozowski, T. et al. (2004). Acceleration of ulcer healing by pentadecapeptide BPC 157 in rats. Involvement of endogenous prostaglandins and gastric secretion. Gastroenterology 126, 541.
20. Petek, M., Sikiric, P., Anic, T. et al. (1999). Pentadecapeptide BPC 157 attenuates gastric lesions induced by alloxan in rats and mice. J. Physiol. (Paris) 93, 501-504.
21. Petrovic, I., Dobric I., Drvis, P. et al. (2006). An experimental model of prolonged esophagitis with sphincteric failure in rat and therapeutic potential of pentadecapeptide BPC 157. J. Pharm. Sci. (in press).
22. Prkacin, I., Aralica, G., Perovic, D. et al. (2001a). Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J. Physiol. (Paris) 95, 295-301.
23. Prkacin, I., Separovic, J., Aralica, G. et al. (2001b). Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J. Physiol. (Paris) 95, 315-324.
24. Prkacin, I., Staresinic, M., Suknaic, S. et al. (2002). Reduction of Doppler shift of otherwise increased blood flow velocity in v. cava inferior and v. portae of chronically alcohol drinking portal hypertensive rats by gastric pentadecapeptide BPC 157 (PL-10). Gastroenterology 122, 353.
25. Robert, A. (1979) .Cytoptotection by prostaglandins. Gastroenterology 77, 761-767.
26. Robert, A., Lum, J. T., Lancaster, C., Olafsson, A. S., Kolbasa, K. P., Nezamis, J. E. (1989). Prevention by prostaglandins of caerulein-induced pancreatitis in rats. Lab. Invest. 60, 677-691.
27. Robert. A., Nezamis, J. E, Lancaster, C. et al. (1983). Mild irritants prevent gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. Am. J. Physiol. 245, G113-G1121.
28. Sebecic, B., Nikolic, V., Sikiric, P. et al. (1999). Osteogenic effect of a gastric pentadecapeptide BPC 157, on the healing of segmental bone defect in rabbits. A comparison with bone marrow and autologous cortical bone implantation. Bone 24, 195-202.
29. Seiwerth, S., Sikiric, P., Grabarevic, Z. et al. (1997). BPC 157's effect on helaing. J. Physiol. (Paris) 91, 173-178.
30. Seveljevic Jaran, D., Cuzic, S., Dominis Kramaric, I. et al. (2006). Accelerated healing of excisional skin wounds by PL 14736 in alloxan-hyperglicemic rats. Skin Pharmacol. Physiol. 19, 266-274.
31. Sikiric, P. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10) - a review. Inflammopharmacology 7, 1-14.
32. Sikiric P., Seiwerth S., Grabarevic Z. et al. (1997c). Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammagtory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J. Physiol. (Paris) 91, 113-122.
33. Sikiric, P., Gyires, K., Seiwerth, S. et al. (1993a). The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology 2, 121-127.
34. Sikiric, P., Jadrijevic, S., Seiwerth, S. et al. (1999a). Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J. Physiol. (Paris) 93, 467-477.
35. Sikiric, P., Jelovac, N., Gjeldum, A. et al. (2002) Pentadecapeptide BPC 157 attenuates chronic amphetamine-induced behavior disturbances. Acta Pharmacol. Sin. 23, 412-422.
36. Sikiric, P., Jelovac, N., Jelovac-Gjeldum, A. et al. (2001a). Anxiolytic effect of BPC 157, a gastric pentadecapeptide: shock probe/burying test and light/dark test. Acta Pharmacol. Sin. 22, 225-230.
37. Sikiric, P., Marovic, A., Matoz, W. et al. (1999b). A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropropyridine. J. Physiol. (Paris) 93, 505-512.
38. Sikiric, P., Mazul, B., Seiwerth, S. et al. (1997a). Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig. Dis. Sci. 42, 661-671.
39. Sikiric P., Mikus D., Seiwerth S. et al. (1997b). Pentadecapeptide BPC 157, cimetidine, ranitidine, bromocriptine, and atropine effect in cysteamine lesions in totally gastrectromized rats: a model for cytoprotective studies. Dig. Dis. Sci. 42, 1029-1037.
40. Sikiric, P., Petek, M., Rucman, R. et al. (1993b). A new gastric peptide BPC. An overview of stomach -organoprotection hypothesis and beneficial effect of BPC . J. Physiol. (Paris) 87, 313-327.
41. Sikiric P., Seiwerth S., Aralica G. et al. (2001b). Therapy effect of antiulcer agents on new chronic cysteamine colon lesion in rat. J. Physiol.(Paris) 95, 295-301.
42. Sikiric, P., Seiwerth, S., Deskovic, S. et al. (1999c).New model of cytoprotection/adaptive cytoprotection in rats: endogenous small irritants, antiulcer agents and indomethacin. European J. Pharmacol. 364, 23-31.
43. Sikiric, P., Seiwerth, S., Grabarevic, Z. et al. (1996a). Beneficial effect of novel pentadecapeptide BPC 157 on gastric lesions induced by restraint stress, ethanol, indomethacin, and capsaicin neurotoxicity. Dig. Dis. Sci. 41, 1604-1614.
44. Sikiric, P., Seiwerth, S., Grabarevic, Z. et al. (2001c). Cysteamine-colon and cysteamine-duodenum lesions in rats. Attenuation by gastric pentadecapeptide BPC 157, cimetidine, ranitidine, atropine, omeprazole, sulphasalazine and methylprednisolone. J. Physiol. (Paris) 95, 261-270.
45. Sikiric, P., Seiwerth, S., Grabarevic, Z. et al. (1994). The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesion induced by restraint stress, cysteamine and 96 % ethanol in rats. A comparative study with H2 receptor antagonists, dopamine promoters and gut peptides. Life Sci. 54, PL63-PL68.
46. G-nitro-L-arginine methylester and L-arginine effect on stomach mucosal integrity and blood pressure. European J. Pharmacol. 332, 23-33.
47. Sikiric, P., Seiwerth, S., Mise, S. et al. (2003). Corticosteroids-impairment healing and gastric pentadecapeptide BPC 157 creams in burned mice. Burns. 29, 323-334.
48. Sikiric, P., Seiwerth, S., Grabarevic, Z. et al. (1996b). Salutary and prophylactic effect of pentadecapeptide BPC 157 on acute pancreatitis and concomitant gastroduodenal lesions in rats. Dig. Dis. Sci. 41, 1518-1526.
49. Sikiric, P., Seiwerth, S., Grabarevic, Z. et al. (1993c). Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restrant stress or bile duct and hepatic artery ligation or CC14 adminstration. A comparative study with dopamine agonists and somatostatin. Life Sci. 53, PL291-PL296.
50. Sikiric, P., Separovic, J., Anic, T. et al. (1999d). The effect of pentadecapeptide BPC 157, H2-blockers, omeprazole and sucralfate on new vessels and new granulation tissue formation. J. Physiol. (Paris) 93, 479-485.
51. Sikiric, P., Separarovic, J., Buljat, G. et al. (2000a). Gastric mucosal lesions induced by complete dopamine system failure in rats. The effects of dopamine agents, ranitidine, atropine, omeprazole and pentadecapeptide BPC 157. J. Physiol. (Paris) 94, 105-110.
52. Sikiric, P., Separovic, J., Buljat, G. et al. (2000b). The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J. Physiol. (Paris) 94, 99-104.
53. Skorjanec, S., Dolovski, Z., Brcic, L. et al. (2006). Gastric pentadecapeptide BPC 157 heals gastrocutaneous fistula in rats. Digestion 73 (Suppl 2), 46.
54. Stancic-Rokotov, D., Sikiric, P., Seiwerth, S. et al. (2001a). Ethanol gastric lesion aggravated by lung injury in rat. Therapeutic effect of antiulcer agents. J. Physiol. (Paris) 95, 289-293.
55. Stancic-Rokotov, D., Slobodnjak, Z., Aralica, J. et al. (2001b). Lung lesions and anti-ulcer agents beneficial effect: anti-ulcer agents pentadecapeptide BPC 157, ranitidine, omeprazole and atropine ameliorate lung lesion in rat. J. Physiol. (Paris) 95, 303-308.
56. Staresinic, M., Petrovic, I., Novinscak, T. et al. (2006). Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J. Orthopaed. Res. 24, 1109-1117.
57. Staresinic, M., Sebecic, B., Jadrijevic, S. et al. (2003).Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J. Orthopaed. Res. 21, 976-983.
58. Szabo, S. (1986). Experimental basis for a role of sulfhydryls and dopamine in ulcerogenesis: a primer for cytoprotection-organoprotection. Klin. Wochenschr. 64, 116-122.
59. Szabo, S., Neumeyer, J. L. (1983). Dopamine agonists and antagonists in duodenal ulcer disease, in: ACS Symposium Series, Kaiser, C. and Kebabian, W. (Eds). 224, pp. 175-196. American Chemical Society Publications, Washington, USA.
60. Thompson, J. C., Greeley, G. H., Rayford, P. L., Townsend, C. M. (1987). Gastrointestinal endocrinology. McGraw-Hill Book Company, New York, USA.
61. Szabo, S., Trier, J. S., Brown, A. et al. (1985). Early vascular injury and increased vascular permeability in gastric mucosal injury caused by ethanol in the rat. Gastroenterology 88, 228-236.
62. Szabo, S., Usadel, K. H. (1982). Cytoprotection-organoprotection by somatostatin: gastric and hepatic lesions. Experientia 38, 254-256.
63. Tohyama, Y., Sikiric, P., Diksic, M. (2004). Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L- tryptophan autoradiographic measurements. Life Sci. 76, 345-357.
64. Turkovic, B., Sikiric, P., Seiwerth, S. et al. (2004).Stable gastric pentadecapeptide BPC 157 studied for inflammatory bowel disease (PLD-116, PL14736, Pliva) induces nitric oxide synthesis. Gastroenterology 126, 287.
65. Urist, M. R. (1996). The first three decades of bone morphogenetic protein. Osteologie 4, 207-233.
66. Veljaca, M., Chan, K., Guglietta, A. (1995). Digestion of h-EGF, h-TGF alpha and BPC-15 in human gastric juice. Gastroenterology 108, 761.
67. Veljaca, M., Krnic, Z. Brajsa, K. et al. (2002). The development of PL 14736 for treatment of inflammatory bowel disease. IUPHAR-GI Section Symposium, Honolulu, Hawaii. 13-15 July, 0-32.
68. Veljaca, M., Lesch C. A., Pllana, R., Sanchez, B., Chan, K., Guglietta, A. (1994). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. J. Pharmacol. Exp. Ther. 272, 417-422.
69. Veljaca, M., Pavic Sladoljev, D., Mildner, B. et al. (2003).Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers. Gut 51 (Suppl III), A309.
70. Wood, J. D. (2004). The first Nobel prize for integrated systems physiology: Ivan Petrovich Pavlov, 1904. Physiology 19, 326-330.
71. Whittle, B. J. R., Boughton-Smith, N. K., Moncada, S. (1992). Biosynthesis and role of the endothelium-derived vasodilator, nitric oxide in gastric mucosa. Ann. N.Y. Acad. Sci. 664, 126-139.
72. Zoricic, I., Sikiric, P., Seiwerth, S. (1997). Pentadecapeptide BPC 157 beneficially influences the healing of colon-colon anastomoses in rats, in: Cell injury and protection in the gastrointestinal tract. From basic sciences to clinical perspectives 1996. Mozsik, G., Nagy, L., Par, A., Rainsford, K. D. (Eds), pp.249-58. Kluwer Academic Publishers, Dodrecht, Boston, London.
73. Xue, X. C., Wu, Y. J., Gao, M. T. (2004a). Study of the protective effects of pentadecapeptide BPC 157 on wounds in small type pigs. Chin. New Drugs J. 12, 602-604.
74. Xue, X. C., Wu, Y. J., Gao, M. T. et al. (2004b). Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J. Gastroenterol. 10, 1032-1036.